Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05145439
Other study ID # S21-003
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 14, 2023
Est. completion date December 13, 2023

Study information

Verified date April 2024
Source Vibrato Medical, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is evaluating whether a therapeutic ultrasound device can improve blood flow to the leg with diabetic foot ulcer (DFU).


Description:

The VibratoSleeve TUS will be used on to assess its acute vasodilatory and perfusion effects in diabetic subjects with PAD and DFU. Each subject will receive one 90-minute TUS treatment in each of 3 treatment sessions. All post-treatment acute assessments will take place immediately following each day's treatment and no follow-up assessments will be required in this study.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date December 13, 2023
Est. primary completion date November 10, 2023
Accepts healthy volunteers No
Gender All
Age group 22 Years and older
Eligibility Inclusion Criteria: 1. Presence of at least one DFU (grade 0 or 1 by University of Texas classification) 2. Diagnosis of diabetes mellitus 3. Diagnosis of PAD that meets at least one of the following conditions: 1. Ankle-brachial index (ABI) of < 0.9 in the same limb as the DFU 2. Toe Brachial Index (TBI) = 0.6 OR Toe Blood Pressure = 50 mmHg 3. Documented history of PAD for a minimum of 3 calendar months prior to time of enrollment 4. Aged = 22 years Exclusion Criteria: 1. Rutherford 6 stage PAD 2. Active DFU infection 3. End-stage renal disease on dialysis 4. HbA1c > 13%. 5. Planned PAD revascularization. 6. Prior stenting in posterior tibial artery. 7. Re-vascularization procedure within 25 days prior to enrollment in the study. (Note: Patients who had re-vascularization procedure earlier than 25 days prior to enrollment are eligible for enrollment if they meet all other criteria). 8. History or diagnosis of severe chronic venous insufficiency or mixed arterio-venous disease. 9. Acute limb ischemia within 30 days prior to treatment. 10. History or diagnosis of deep venous thrombosis below the knee in treatment leg. 11. Any conditions that, in the opinion of the investigator, may render the patient unable to complete the study or lead to difficulties for patient compliance with study requirements, or could confound study data. 12. Patient's enrollment in another investigational study that has not completed the required primary endpoint follow-up period (Note: Patients involved in a long-term surveillance phase of another study are eligible for enrollment in this study).

Study Design


Intervention

Device:
VibratoSleeve Therapeutic Ultrasound Device
The VibratoSleeve is compromised of a 16-transducer array that is mounted within a wrap that conforms to the posterior calf.

Locations

Country Name City State
United States Vascular & Interventional Specialists of Orange County Orange California

Sponsors (3)

Lead Sponsor Collaborator
Vibrato Medical, Inc. National Institutes of Health (NIH), Vascular and Interventional Specialists of Orange County, Inc. (VISOC)

Country where clinical trial is conducted

United States, 

References & Publications (2)

Kalani M, Brismar K, Fagrell B, Ostergren J, Jorneskog G. Transcutaneous oxygen tension and toe blood pressure as predictors for outcome of diabetic foot ulcers. Diabetes Care. 1999 Jan;22(1):147-51. doi: 10.2337/diacare.22.1.147. — View Citation

Yang C, Weng H, Chen L, Yang H, Luo G, Mai L, Jin G, Yan L. Transcutaneous oxygen pressure measurement in diabetic foot ulcers: mean values and cut-point for wound healing. J Wound Ostomy Continence Nurs. 2013 Nov-Dec;40(6):585-9. doi: 10.1097/WON.0b013e3 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Transcutaneous Oxygen Pressure (TcPO2) TcPO2 is a noninvasive test that directly measures the oxygen level of tissue beneath the skin. Through study completion, an average of 1 month.
Secondary Perfusion rate of the targeted foot Perfusion to be measured with the FlowMet Device (Medtronic) Through study completion, an average of 1 month
Secondary DFU tissue oxygenation (StO2) and the hemoglobin content (HbT2) To be measured with the Clarifi device (Modulim) Through study completion, an average of 1 month
Secondary Ankle Brachial Index (ABI) per institutional standards of care Through study completion, an average of 1 month
See also
  Status Clinical Trial Phase
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Active, not recruiting NCT03987061 - MOTIV Bioresorbable Scaffold in BTK Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Active, not recruiting NCT04677725 - NEtwork to Control ATherothrombosis (NEAT Registry)
Recruiting NCT05961943 - RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients N/A
Recruiting NCT06047002 - Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
Completed NCT03185052 - Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach N/A
Recruiting NCT05992896 - A Study of Loco-Regional Liposomal Bupivacaine Injection Phase 4
Completed NCT04635501 - AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Withdrawn NCT03994185 - The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease N/A
Withdrawn NCT03538392 - Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
Recruiting NCT02915796 - Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty Phase 1
Active, not recruiting NCT02900924 - Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
Completed NCT02901847 - To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities. N/A
Not yet recruiting NCT02455726 - Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease N/A
Withdrawn NCT02126540 - Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries N/A
Not yet recruiting NCT02387450 - Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication Phase 2/Phase 3
Completed NCT02022423 - Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease N/A